Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10933060 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
US10973811 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
US10987347 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
US10894012 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
US10857095 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
US10231961 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
US11040032 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
US10016407 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
US9867815 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
US10413505 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
US10420760 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
US10149843 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 14, 2022 |
Drugs and Companies using COCAINE HYDROCHLORIDE ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 14 December, 2017
Treatment: Method for the induction of local anesthesia of the mucous membranes; Method of administering a local anesthetic to the mucous membranes in patients with renal impairment; Method of administering a local anesthetic to the mucous membranes in patients with hepatic impairment; Method of administering a local anesthetic prior to performing a diagnostic or surgical procedure on a subject with hepatic or renal impairment; Method of administering a local anesthetic to the mucous membranes in geriatric patients; Method of administering a local anesthetic to the mucous membranes; Method for the induction of local anesthesia prior to performing a procedure on, through, or adjacent to the mucous membranes
Dosage: SOLUTION;NASAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10231931 | GENUS LIFESCIENCES | Thyroid hormone oral dosage forms and methods of using the same |
Mar, 2038
(15 years from now) | |
US10406108 | GENUS LIFESCIENCES | Thyroid hormone oral dosage forms and methods of using the same |
Mar, 2038
(15 years from now) |
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 06 June, 2003
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9364439 | GENUS LIFESCIENCES | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May, 2022
(7 months ago) | |
US6926907 | GENUS LIFESCIENCES | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
Feb, 2023
(a month from now) | |
US8206741 | GENUS LIFESCIENCES | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
Feb, 2023
(a month from now) | |
US9987231 | GENUS LIFESCIENCES | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
Jan, 2033
(9 years from now) | |
US9539214 | GENUS LIFESCIENCES | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
Mar, 2033
(10 years from now) |
Drugs and Companies using ASPIRIN; OMEPRAZOLE ingredient
Market Authorisation Date: 14 September, 2016
Treatment: Treatment or secondary prevention of cardiovascular disease, cardiovascular events, or cerebrovascular events and risk-reduction of aspirin-associated gastric ulcers; For secondary prevention of cardiovascular and cerebrovascular events in patients at risk of developing aspirin-associated gastric ulcers
Dosage: TABLET, DELAYED RELEASE;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic